Literature DB >> 199059

Antibodies to Epstein-Barr virus capsid antigen and early antigen in nasopharyngeal carcinoma and comparison groups.

T M Lin, C S Yang, J F Chiou, S M Tu, T Y Chen, Y C Tu, P J Lin, A Kawamura, T Hirayama.   

Abstract

Antibodies to Epstein-Barr virus capsid antigen (anti-VCA) and early antigen (anti-EA) were measured in 263 patients with nasopharyngeal carcinoma (NPC), 624 age- and sex-matched neighborhood controls, 570 family members of NPC patients and 830 family members of neighborhood controls in Taiwan. The distribution of antibody titers was significantly different between NPC patients and the other three groups. More than 55% and 45% of NPC patients had titers of greater than or equal to 1:640 and greater than or equal to 1:80 for anti-VCA and anti-EA, respectively, while less than 6.7% and 2.5% of the other three groups had such high titers. The geometric means of anti-VCA and anti-EA titers were 1:352 and 1:45, respectively, in NPC patients compared to less than 1:77 and 1:12, respectively, in the comparison groups. Anti-VCA and anti-EA titers were significantly correlated. The association of EBV with NPC is discussed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 199059     DOI: 10.1093/oxfordjournals.aje.a112470

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  2 in total

1.  Validation of an Epstein-Barr Virus Antibody Risk Stratification Signature for Nasopharyngeal Carcinoma by Use of Multiplex Serology.

Authors:  Julia Simon; Zhiwei Liu; Allan Hildesheim; Tim Waterboer; Nicole Brenner; Kelly J Yu; Wan-Lun Hsu; Cheng-Ping Wang; Yin-Chu Chien; Anna E Coghill; Chien-Jen Chen; Julia Butt; Carla Proietti; Denise L Doolan
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

2.  Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.

Authors:  Min-Jie Mao; Ning Xue; Xue-Ping Wang; Pei-Dong Chi; Yi-Jun Liu; Qi Huang; Shu-Qin Dai; Wan-Li Liu
Journal:  BMC Cancer       Date:  2018-01-02       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.